Menu
B

Biomedica Research Group | Santiago, Chile

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

BIIB059
Litifilimab
Gantenerumab
Iclepertin
Pimavanserin
Etrasimod
Deucravacitinib
ACP-204
PF-05212377
mRNA-1345

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Active trials

In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with cutaneous lupus erythematosus (CLE)....

Enrolling
Subacute Cutaneous Lupus Erythematosus
Chronic Cutaneous Lupus Erythematosus
Drug: Litifilimab
Drug: Placebo

The purpose of this study is to evaluate the efficacy, safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of orally administered...

Enrolling
Dermatomyositis
Drug: Placebo
Drug: GLPG3667

The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-cent...

Active, not recruiting
Atrial Fibrillation
Drug: Apixaban Placebo
Drug: Milvexian

The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe System...

Enrolling
Systemic Lupus Erythematosus
Drug: Deucravacitinib
Other: Placebo

The purpose of this study is to assess the safety and efficacy of two doses of Deucravacitinib in adult participants with Active Sjögren's Syndrome.

Enrolling
Sjögren's Syndrome
Other: Placebo
Drug: Deucravacitinib

The main purpose of Part A of this study is to evaluate the safety and tolerability of mRNA-1345 vaccine and to demonstrate the efficacy of a single...

Active, not recruiting
Respiratory Syncytial Virus
Drug: Placebo
Drug: mRNA-1345
Locations recently updated

In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with systemic lupus erythematosus (SLE). T...

Enrolling
Lupus Erythematosus, Systemic
Drug: Placebo
Drug: Litifilimab

This is a master protocol for 3 independent, seamlessly enrolling, multicenter, randomized, double-blind, placebo-controlled, parallel-group studies...

Enrolling
Alzheimer's Disease Psychosis
Drug: Placebo
Drug: ACP-204

This 52-week, open-label extension study is to evaluate the long-term safety and tolerability of ACP-204 in subjects with ADP.

Invitation-only
Alzheimer's Disease Psychosis
Drug: ACP-204

In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with systemic lupus erythematosus (SLE). T...

Invitation-only
Systemic Lupus Erythematosus (SLE)
Drug: Litifilimab-matching placebo
Drug: Litifilimab

This is a Phase 3, multicenter, randomized, double-blind, safety and efficacy study of contezolid acefosamil (IV)/contezolid (PO) compared with linez...

Enrolling
Diabetic Foot Infection
Drug: contezolid acefosamil (IV)/contezolid (PO)
Drug: Linezolid (IV and PO)
Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trial sponsors

Acadia Pharmaceuticals logo
Pfizer logo
Biogen logo
Roche logo
A
Boehringer Ingelheim logo
Bristol-Myers Squibb (BMS) logo
Janssen (J&J Innovative Medicine) logo
G
G